×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$191.04
+6.68 (+3.62%)
(As of 07/1/2022 05:43 PM ET)
Add
Compare
Today's Range
$183.19
$191.33
50-Day Range
$181.58
$319.10
52-Week Range
$180.00
$526.00
Volume
1.12 million shs
Average Volume
1.16 million shs
Market Capitalization
$30.01 billion
P/E Ratio
41.53
Dividend Yield
N/A
Price Target
$425.09

Illumina Stock Forecast (MarketRank)

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
122.5% Upside
$425.09 Price Target
Short Interest
Healthy
2.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.26mentions of Illumina in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.75 M Sold Last Quarter
Proj. Earnings Growth
28.78%
From $4.10 to $5.28 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.42 out of 5 stars

Medical Sector

205th out of 1,429 stocks

Analytical Instruments Industry

7th out of 33 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Illumina logo

About Illumina (NASDAQ:ILMN)

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

ILMN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,150
Year Founded
1998

Company Calendar

Last Earnings
5/05/2022
Today
7/02/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$425.09
High Stock Price Forecast
$520.00
Low Stock Price Forecast
$325.00
Forecasted Upside/Downside
+122.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
9 Analysts

Profitability

Net Income
$762 million
Pretax Margin
18.37%

Debt

Sales & Book Value

Annual Sales
$4.53 billion
Cash Flow
$7.40 per share
Book Value
$68.71 per share

Miscellaneous

Free Float
156,896,000
Market Cap
$30.01 billion
Optionable
Optionable
Beta
1.01

Social Links















Illumina Frequently Asked Questions

Should I buy or sell Illumina stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina
or view top-rated stocks.

What is Illumina's stock price forecast for 2022?

9 brokerages have issued 12 month price objectives for Illumina's shares. Their ILMN stock forecasts range from $325.00 to $520.00. On average, they expect Illumina's stock price to reach $425.09 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price.
View analysts' price targets for Illumina
or view top-rated stocks among Wall Street analysts.

How has Illumina's stock price performed in 2022?

Illumina's stock was trading at $380.44 at the beginning of 2022. Since then, ILMN stock has decreased by 49.8% and is now trading at $191.04.
View the best growth stocks for 2022 here
.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings data on Thursday, May, 5th. The life sciences company reported $1.07 EPS for the quarter, topping the consensus estimate of $0.87 by $0.20. The life sciences company earned $1.22 billion during the quarter, compared to analysts' expectations of $1.22 billion. Illumina had a net margin of 15.04% and a trailing twelve-month return on equity of 8.37%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.89 EPS.
View Illumina's earnings history
.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of $4.00-$4.20 for the period, compared to the consensus EPS estimate of $4.15. The company issued revenue guidance of $5.16 billion-$5.25 billion, compared to the consensus revenue estimate of $5.23 billion.

Who are Illumina's key executives?

Illumina's management team includes the following people:

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $191.04.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $30.01 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or $4.599990 on an earnings per share basis.

How many employees does Illumina have?

Illumina employs 9,150 workers across the globe.

Does Illumina have any subsidiaries?

The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Edico Genome Corp., Enancio, Enancio SAS, Epicentre Biotechnologies, Epicentre Technologies Corporation, FC Ops Corp., GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada Inc., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Holding Sarl, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina Iceland ehf, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus, Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More

When was Illumina founded?

Illumina was founded in 1998.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for Illumina is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at [email protected], or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.